Compare Amgen, Inc. (AMGN) vs OneSpan Inc (OSPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs OneSpan Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while OneSpan Inc trades at $15.17 (market cap $561.84M). The key difference: Amgen, Inc. is far larger — about 349.1× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.43%). Which is the better fit depends on your goals.
| AMGN | OSPN | |
|---|---|---|
Market Cap | $196.12B | $561.84M |
Sector | Health | Technology |
52-Week High | $388.16 | $16.32 |
52-Week Low | $271.18 | $10.15 |
Enterprise Value | $241.41B | $520.04M |
Dividend Yield | 2.77% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
OneSpan (OSPN) trades at $15.17, down slightly by 0.26% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 28.47% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights investor attention and the upcoming Q2 2026 earnings release on August 4, 2026, alongside strategic leadership appointments to accelerate growth.
The outlook remains positive given consistent earnings beats and high analyst buy ratings, though risks include negative cash flow trends and competitive pressures. Upside potential exists if the company maintains its earnings momentum, but investors should monitor cash flow improvements and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
